TrialStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2016

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Monika Rucinska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.